Valuation: Pulse Biosciences, Inc.

Market Cap 3.27B 2.98B 2.75B 2.49B 4.67B 305B 4.89B 33.3B 13.21B 165B 12.25B 12B 522B P/E 2026 *
-33.9x
P/E 2027 * -30.7x
Enterprise Value 3.27B 2.98B 2.75B 2.49B 4.67B 305B 4.89B 33.3B 13.21B 165B 12.25B 12B 522B EV / Sales 2026 *
1,843x
EV / Sales 2027 * 717x
Free-Float
31%
Yield 2026 *
-
Yield 2027 * -
1 day-3.10%
1 week-22.06%
Current month-14.99%
1 month-0.05%
3 months-3.46%
6 months+73.41%
Current year+223.45%
1 week 43.14
Extreme 43.14
54.25
1 month 43.14
Extreme 43.14
58.94
Current year 13.17
Extreme 13.17
58.94
1 year 12.56
Extreme 12.56
58.94
3 years 6.01
Extreme 6.01
58.94
5 years 1.18
Extreme 1.18
58.94
10 years 1.18
Extreme 1.18
58.94
Manager TitleAgeSince
Chief Executive Officer 68 2025-01-08
Director of Finance/CFO 40 2025-02-02
Chief Operating Officer 49 2026-04-07
Director TitleAgeSince
Director/Board Member 60 2015-09-14
Director/Board Member 55 2017-02-09
Chairman 81 2017-11-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Buy

Chief Operating Officer

1,001 0.0014%
8/28/26 Buy

Chief Operating Officer

1,034 0.0015%
8/8/26 Free

Chief Operating Officer

900,000 1.3004%
Change 5-day change 1-year change 3-year change Capi.($)
-3.10%-22.06%+227.03%+625.65% 3.37B
-0.58%-4.04%+19.57%+47.67% 257B
-0.45%-3.29%+0.91%+9.52% 161B
-3.26%-9.41%-25.52%+33.40% 146B
-1.49%-4.74%-56.67%-20.89% 63.26B
-1.28%-1.82%+23.61%+55.28% 60.51B
-0.05%+0.69%+5.41%-12.43% 53.46B
-1.12%-0.91%+21.90%+54.96% 49.99B
-5.15%-13.73%-3.95%+48.93% 44.88B
-2.06%-3.06%+21.20%+74.31% 45.81B
Average -1.85%-5.01%+23.35%+91.64% 88B
Weighted average by Cap. -1.43%-4.01%+2.52%+34.42%

Financials

2026 *2027 *
Net sales 1.77M 1.61M 1.49M 1.35M 2.54M 165M 2.65M 18.07M 7.17M 89.43M 6.65M 6.51M 283M 4.56M 4.15M 3.84M 3.48M 6.52M 426M 6.83M 46.47M 18.43M 230M 17.1M 16.74M 729M
Net income -91.82M -83.66M -77.44M -70.05M -131M -8.58B -138M -936M -371M -4.63B -344M -337M -14.68B -105M -95.95M -88.82M -80.34M -151M -9.84B -158M -1.07B -426M -5.31B -395M -387M -16.84B
Net Debt - -
Projected Income Statement - Annual - Pulse Biosciences, Inc.
Logo Pulse Biosciences, Inc.
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Employees
116
Date Price Change Volume
26-11-19 US$44.41 -3.10% 271,602
26-11-18 US$45.83 +2.21% 332,035
26-11-17 US$44.84 -3.28% 628,539
26-11-16 US$46.36 -8.09% 487,213
26-11-13 US$50.44 -3.46% 590,842
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Pulse Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
44.41USD
Average target price
67.67USD
Spread / Average Target
+52.37%
  1. Stock Market
  2. Stocks
  3. PLSE Stock